130442-10-3

Basic information

• Product Name: Phenol, 3-(tetradecyloxy)-
• CAS NO: 130442-10-3
• Molecular Formula: C20H34O2
• Molecular Weight: 306.489
• Mol File: 130442-10-3.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Phenol, 3-(tetradecyloxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Phenol, 3-(tetradecyloxy)-(130442-10-3)
• EPA Substance Registry System: Phenol, 3-(tetradecyloxy)-(130442-10-3)

Safety Data

• Hazardous Substances Data: 130442-10-3(Hazardous Substances Data)

Upstream product

• 72422-53-8 toluene-4-sulfonic acid tetradecyl ester 
• 54494-87-0 resorcinol; sodium-compound 
• 112-71-0 1-Bromotetradecane 
• 108-46-3 recorcinol 

Downstream Products

• 1058053-17-0 C₄₈H₆₈N₂O₄ 
• 1331960-72-5 C₅₅H₉₅NO₅ 
• 1331961-30-8 C₂₀H₃₃NO₄ 
• 1331960-67-8 2-hydroxy-4-tetradecyloxy-N-(2-hydroxy-4-tetradecyloxybenzylidene)aniline 
• 1331960-59-8 2,3-ditetradecyloxy-6-(6-tetradecyloxybenzooxazol-2-yl)phenol 
• 1331960-54-3 5-tetradecyloxy-2-(6-tetradecyloxybenzoxazol-2-yl)phenol 
• 130442-11-4 3-(bromomethyl)phenyl 3-(tetradecyloxy)phenyl phosphate 
• 140467-60-3 1-[(4-Methoxy-phenyl)-diphenyl-methoxy]-3-(3-tetradecyloxy-phenoxy)-propan-2-ol 
• 140467-95-4 Phosphoric acid 3-bromomethyl-phenyl ester 2-methoxy-3-(3-tetradecyloxy-phenoxy)-propyl ester 
• 140467-75-0 2-Methoxy-3-(3-tetradecyloxy-phenoxy)-propan-1-ol 
• 140468-18-4 3-(3-Tetradecyloxy-phenoxy)-propane-1,2-diol 
• 140468-09-3 2,2-Dimethyl-4-(3-tetradecyloxy-phenoxymethyl)-[1,3]dioxolane 

Relevant articles and documents

Polarization effect in luminescent mesogenic BF2 complexes derived from heterocyclic benzothiazoles

Two series of benzo(thia)xazoles 1–2 and one series of boron difluoride complexes 2-BF2 derived from benzothiazoles 2 were reported, and their mesomorphic and optical properties were investigated. The crystal and molecular structures of compound 2 and 2-BF2 (all n = 8) were determined by means of X?ray structural analysis, and both crystallize in the triclinic P-1 and monoclinic P21/c. The geometry at boron center is perfectly tetrahedral, and the overall molecular shapes are considered as rod?shape. Both benzo(thia)xazoles 1 and 2 exhibited N or/and SmC phase, and boron complexes 2-BF2 formed N or/and SmC phase. Benzothiazoles 2 showed a much wider temperature range of mesophase than those of benzoxazoles 1, which were attributed to the better polarization by sulfur atom incorporated. Boron complexes 2-BF2 (n = 10, 12) emitted a yellow?to?green emission at λmax = 569–571 nm in CH2Cl2. This is the first mesogenic BF2 complexes derived from benzothiazoles.

Discotic liquid crystals of transition metal complexes 45?: Parity effect of the number of d-electrons on stacking distances in the columnar mesophases of octakis-(M-alkoxyphenoxy)phthalocyaninato metal(II) complexes

We have synthesized 34 novel homologous discotic liquid crystals, octakis(m-alkoxyphenoxy)phthalocyaninato metal(II) {abbreviated as (m-C nOPhO)8PcM (M = Co(1), Ni(2), Cu(3), Zn(4) and H 2(5); n = 8(a), 10(b), 12(c), 14(d)

Analogues of Platelet Activating Factor. 6. Mono- and Bis-Aryl Phosphate Antagonists of Platelet Activating Factor

A series of aryl phosphoglyceride (3, 19-61) and bis-aryl phosphate (67-135) antagonists of platelet activating factor (PAF) were prepared.A group of four bifunctional phosphorus reagents (5a-c and 7) were developed that allowed the preparation of these aryl phosphates in which the position of aromatic substitution can be varied.These compounds were examined for their ability to inhibit PAF-induced platelet aggregation of rabbit platelets.Selected compounds were also evaluated for their ability to displace PAF from its receptor on rabbit platelets.These in vitro data were compared to similar data obtained for a number of known PAF antagonists.The compounds were evaluated in vivo, in both the mouse and rabbit, for their ability to prevent death induced by a lethal challenge of PAF.The relationships between the biological activity and the nature, lipophilicity, and position of substituents of the aromatic rings were studied.Compound 105 (CL 184005) has been selected to undergo further development as a potential therapeutic agent for the treatment of septic shock in man.